Hoth Therapeutics is resuming its At-The-Market (ATM) offering program. The company previously suspended the prospectus supplement on April 1, 2026. A new prospectus supplement is being filed to facilitate the sale of up to $1,555,000 in common stock. The underlying Sales Agreement with H.C. Wainwright & Co., LLC, dated November 8, 2024, remains in effect.